Ignite Creation Date:
2025-12-24 @ 11:48 AM
Ignite Modification Date:
2026-01-29 @ 6:04 AM
Study NCT ID:
NCT06093061
Status:
RECRUITING
Last Update Posted:
2025-05-11
First Post:
2023-10-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Sponsor:
National Cancer Centre, Singapore
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Nasopharyngeal Carcinoma | View |